WO2014051164A3 - Production method of thienopyrimidine derivative - Google Patents

Production method of thienopyrimidine derivative Download PDF

Info

Publication number
WO2014051164A3
WO2014051164A3 PCT/JP2013/077013 JP2013077013W WO2014051164A3 WO 2014051164 A3 WO2014051164 A3 WO 2014051164A3 JP 2013077013 W JP2013077013 W JP 2013077013W WO 2014051164 A3 WO2014051164 A3 WO 2014051164A3
Authority
WO
WIPO (PCT)
Prior art keywords
salt
production method
thienopyrimidine derivative
provides
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2013/077013
Other languages
French (fr)
Other versions
WO2014051164A2 (en
Inventor
Koichiro Fukuoka
Kazuhiro Miwa
Tsuyoshi Sasaki
Fumiya KOMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014051164(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL13779938T priority Critical patent/PL2900675T3/en
Priority to EP13779938.3A priority patent/EP2900675B1/en
Priority to EP18185835.8A priority patent/EP3415517B1/en
Priority to ES13779938T priority patent/ES2724206T3/en
Priority to RS20190473A priority patent/RS58703B1/en
Priority to CA2881132A priority patent/CA2881132C/en
Priority to CN201380051107.2A priority patent/CN104703992B/en
Priority to PL18185835T priority patent/PL3415517T3/en
Priority to LTEP13779938.3T priority patent/LT2900675T/en
Priority to SM20190255T priority patent/SMT201900255T1/en
Priority to SI201331414T priority patent/SI2900675T1/en
Priority to DK13779938.3T priority patent/DK2900675T3/en
Priority to US14/432,188 priority patent/US9758528B2/en
Priority to JP2014557263A priority patent/JP6250564B2/en
Priority to CN202110609164.4A priority patent/CN113372358B/en
Priority to EP22168256.0A priority patent/EP4119564A1/en
Priority to HRP20190729TT priority patent/HRP20190729T1/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of WO2014051164A2 publication Critical patent/WO2014051164A2/en
Publication of WO2014051164A3 publication Critical patent/WO2014051164A3/en
Anticipated expiration legal-status Critical
Priority to US15/481,505 priority patent/US10150778B2/en
Priority to US16/034,002 priority patent/US10464945B2/en
Priority to US16/116,804 priority patent/US10544160B2/en
Priority to CY20191100544T priority patent/CY1121641T1/en
Priority to US16/710,390 priority patent/US11053257B2/en
Priority to US17/349,584 priority patent/US11731983B2/en
Priority to US17/694,635 priority patent/US11795178B2/en
Priority to US18/121,886 priority patent/US12180224B2/en
Priority to US18/927,346 priority patent/US12325714B2/en
Priority to US19/201,728 priority patent/US20250368660A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1'-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.
PCT/JP2013/077013 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative Ceased WO2014051164A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DK13779938.3T DK2900675T3 (en) 2012-09-28 2013-09-27 PROCEDURE FOR MANUFACTURE OF A THIENOPYRIMIDINE DERIVATIVE
CN202110609164.4A CN113372358B (en) 2012-09-28 2013-09-27 Preparation method of thienopyrimidine derivatives
EP18185835.8A EP3415517B1 (en) 2012-09-28 2013-09-27 Crystalline form of 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin-6yl)phenyl)-3-methoxyurea
ES13779938T ES2724206T3 (en) 2012-09-28 2013-09-27 Production method of a thienopyrimidine derivative
RS20190473A RS58703B1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
CA2881132A CA2881132C (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
CN201380051107.2A CN104703992B (en) 2012-09-28 2013-09-27 Preparation method of thienopyrimidine derivatives
PL18185835T PL3415517T3 (en) 2012-09-28 2013-09-27 Crystalline form of 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin-6yl)phenyl)-3-methoxyurea
HRP20190729TT HRP20190729T1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
SM20190255T SMT201900255T1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
SI201331414T SI2900675T1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
EP13779938.3A EP2900675B1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
US14/432,188 US9758528B2 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
JP2014557263A JP6250564B2 (en) 2012-09-28 2013-09-27 Method for producing thienopyrimidine derivative
EP22168256.0A EP4119564A1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
PL13779938T PL2900675T3 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
LTEP13779938.3T LT2900675T (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
US15/481,505 US10150778B2 (en) 2012-09-28 2017-04-07 Production method of thienopyrimidine derivative
US16/034,002 US10464945B2 (en) 2012-09-28 2018-07-12 Crystalline forms of thienopyrimidine derivative
US16/116,804 US10544160B2 (en) 2012-09-28 2018-08-29 Production method of thienopyrimidine derivative
CY20191100544T CY1121641T1 (en) 2012-09-28 2019-05-21 METHOD OF PREPARING A THIENOPYRIMIDINE DERIVATIVE
US16/710,390 US11053257B2 (en) 2012-09-28 2019-12-11 Production method of thienopyrimidine derivative
US17/349,584 US11731983B2 (en) 2012-09-28 2021-06-16 Production method of thienopyrimidine derivative
US17/694,635 US11795178B2 (en) 2012-09-28 2022-03-14 Compositions of thienopyrimidine derivatives
US18/121,886 US12180224B2 (en) 2012-09-28 2023-03-15 Thienopyrimidine derivatives and production methods thereof
US18/927,346 US12325714B2 (en) 2012-09-28 2024-10-25 Compositions of thienopyrimidine derivatives
US19/201,728 US20250368660A1 (en) 2012-09-28 2025-05-07 Thienopyrimidine derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012217679 2012-09-28
JP2012-217679 2012-09-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/432,188 A-371-Of-International US9758528B2 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
US15/481,505 Division US10150778B2 (en) 2012-09-28 2017-04-07 Production method of thienopyrimidine derivative

Publications (2)

Publication Number Publication Date
WO2014051164A2 WO2014051164A2 (en) 2014-04-03
WO2014051164A3 true WO2014051164A3 (en) 2014-05-22

Family

ID=49448235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/077013 Ceased WO2014051164A2 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative

Country Status (21)

Country Link
US (10) US9758528B2 (en)
EP (3) EP4119564A1 (en)
JP (1) JP6250564B2 (en)
CN (3) CN113372358B (en)
AR (1) AR092707A1 (en)
CA (1) CA2881132C (en)
CY (2) CY1121641T1 (en)
DK (2) DK3415517T3 (en)
ES (2) ES2913753T3 (en)
HR (2) HRP20220622T1 (en)
HU (2) HUE044048T2 (en)
LT (2) LT2900675T (en)
PL (2) PL2900675T3 (en)
PT (2) PT2900675T (en)
RS (2) RS58703B1 (en)
SI (2) SI2900675T1 (en)
SM (2) SMT202200255T1 (en)
TR (1) TR201906318T4 (en)
TW (3) TWI602819B (en)
UY (1) UY35058A (en)
WO (1) WO2014051164A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10150778B2 (en) 2012-09-28 2018-12-11 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
US10449191B2 (en) 2016-09-30 2019-10-22 Myovant Sciences Gmbh Treatment of prostate cancer
US11033551B2 (en) 2016-09-30 2021-06-15 Myovant Sciences Gmbh Methods of treating uterine fibroids
US12338249B2 (en) 2019-10-10 2025-06-24 Sumitomo Pharma Switzerland Gmbh Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
US12551447B2 (en) 2020-05-29 2026-02-17 Sumitomo Pharma Co., Ltd. Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
US12655154B2 (en) 2019-10-10 2026-06-16 Sumitomo Pharma Co., Ltd. Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744224B (en) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 Solid preparation
WO2018086608A1 (en) * 2016-11-14 2018-05-17 江苏恒瑞医药股份有限公司 Crystalline form of gnrh receptor antagonist and preparation method therefor
EA201992612A1 (en) 2017-06-05 2020-05-20 Обсева С.А. DIAGRAMS OF APPLICATION OF THE GONADOTROPINE-RELAXING HORMONE ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS
CN107188855A (en) * 2017-07-14 2017-09-22 常州工程职业技术学院 A kind of preparation method of the methoxyl group pyridazine of 3 amino 6
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
WO2019178304A1 (en) 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
EP3666776A1 (en) 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
EP3969455A4 (en) * 2019-05-15 2023-07-05 Dr. Reddy's Laboratories Limited Amorphous and crystalline forms of relugolix
CN110194776B (en) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 Synthetic method of Ruogeli
WO2021018105A1 (en) * 2019-07-29 2021-02-04 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
CA3145993A1 (en) * 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112321602A (en) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 Preparation method of Ruogeli drug intermediate
CN112390812A (en) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 Crystalline and amorphous solids of Ruogeli compounds and methods of making the same
CN112771052B (en) * 2019-08-21 2023-04-07 深圳仁泰医药科技有限公司 Crystal form of gonadotropin releasing hormone antagonist and preparation method and application thereof
CN112745304A (en) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 Preparation method of Relugolix and intermediate compound
CN111423452B (en) * 2020-03-26 2023-08-22 江西青峰药业有限公司 Intermediates of Relugoli and their preparation methods and applications
CN113444105A (en) * 2020-03-27 2021-09-28 南京海润医药有限公司 Preparation method of Relugolix
CN111333633B (en) * 2020-04-01 2023-10-20 江西科睿药业有限公司 An intermediate compound of relugoli and its preparation method and use
CN111574534B (en) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 Phenyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN112552312B (en) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 Synthetic method of Ruogeli or salt thereof
CN114685468A (en) * 2020-12-25 2022-07-01 成都硕德药业有限公司 Intermediate compound of medicine for treating hysteromyoma and preparation method thereof
CN113620972A (en) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 Rugosril new crystal form and preparation method thereof
CN114907370B (en) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 High purity thienopyrimidine compounds and process for their preparation
CN115073491A (en) * 2021-03-12 2022-09-20 上海医药工业研究院 Rugosril intermediate, preparation method and application thereof
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
BR112023024454A2 (en) * 2021-06-15 2024-02-06 Wigen Biomedicine Tech Shanghai Co Ltd COMPOUND OF GENERAL FORMULA (1) OR AN ISOMER, A CRYSTALLINE FORM, A PHARMACEUTICALLY ACCEPTABLE SALT, A HYDRATE OR A SOLVATE THEREOF; AND; USE OF THE COMPOUND OR ISOMER
CN115594688B (en) * 2021-06-28 2023-11-17 成都倍特药业股份有限公司 Preparation method of intermediate of Rayleigh Lu Geli
WO2023042214A1 (en) 2021-09-15 2023-03-23 Cipla Limited Solid state forms of relugolix
WO2023066941A1 (en) * 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN114230576A (en) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 A kind of preparation method of Relugoli
WO2023119333A1 (en) * 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
CN114409629B (en) * 2022-02-22 2023-12-29 浙江科聚生物医药有限公司 Preparation method and application of high-purity Relugolix key intermediate
CN114790189B (en) * 2022-02-24 2023-06-09 海化生命(厦门)科技有限公司 Preparation method of intermediate of Rayleigh Lu Geli
CN114755320B (en) * 2022-03-17 2024-10-01 南京方生和医药科技有限公司 Detection method of 3-amino-6-methoxypyridazine related substances
IN202221021078A (en) * 2022-04-08 2023-10-13
CN114621249B (en) * 2022-04-27 2024-01-26 江苏慧聚药业股份有限公司 Preparation of key intermediates of relugoli
CN119546611A (en) 2022-05-05 2025-02-28 台湾神隆股份有限公司 Preparation process of relugolix and its intermediates
CN117069735A (en) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 An efficient method for synthesizing relugoli and its application
CN115594689B (en) * 2022-07-14 2024-03-19 江西同和药业股份有限公司 Synthesis method of Rayleigh Lu Geli intermediate and Rayleigh Lu Geli
CN114989134B (en) * 2022-07-14 2023-11-14 江西同和药业股份有限公司 Thiophene compound and preparation method and application thereof
CN115417883B (en) * 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 Crystal form of rui Lu Geli and preparation method thereof
WO2024069492A1 (en) 2022-09-29 2024-04-04 Macfarlan Smith Limited Processes for the preparation and manufacture of relugolix
CN115650950A (en) * 2022-11-03 2023-01-31 江西同和药业股份有限公司 Rui Lu Geli intermediate and preparation method thereof, and amide condensation method
WO2024126674A1 (en) 2022-12-15 2024-06-20 Medichem, S.A. Process for the preparation of relugolix
CN115650965B (en) * 2022-12-26 2023-03-31 南京威凯尔生物医药科技有限公司 Preparation method of Ruogeli key intermediate
WO2025037218A1 (en) * 2023-08-11 2025-02-20 Glenmark Life Sciences Limited Crystalline solvate of relugolix and a process for its preparation
CN117327091B (en) * 2023-09-28 2026-06-05 浙江天宇药业股份有限公司 A method for synthesizing regrugoli
CN119859136A (en) * 2023-10-19 2025-04-22 诚达药业股份有限公司 Rayleigh Lu Geli key intermediate compound G and preparation method thereof
CN119859135B (en) * 2023-10-19 2025-12-02 浙江工业大学 A relugoli intermediate and its preparation method
WO2025127790A1 (en) 2023-12-12 2025-06-19 주식회사 와이에스생명과학 Method for preparing relugolix

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056739A1 (en) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
EP1266898A1 (en) * 2000-02-29 2002-12-18 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
EP1591446A1 (en) * 2003-01-29 2005-11-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (en) * 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
JP2859791B2 (en) 1992-01-31 1999-02-24 吉富製薬株式会社 Method for producing 4-bromomethylbiphenyl compound
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
FR2710637B1 (en) 1993-09-28 1995-12-08 Roquette Freres Mannitol powder of moderate friability and its preparation process.
JPH10298156A (en) 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd Process for producing substituted halomethylphenylcarbamic acid esters
RU2233284C2 (en) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Thienopyrimidine derivatives, method for their preparing, pharmaceutical composition and method for antagonization of gonadotropin-releasing hormone
JP2001316391A (en) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd Method for producing thienopyridine derivative
GB2361917A (en) * 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002068044A (en) 2000-09-04 2002-03-08 Yamaha Motor Co Ltd Handlebar seat for motorcycle
JP2002088044A (en) * 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd Method for producing 4'-bromomethyl-2-cyanobiphenyl
DE60207280T2 (en) 2001-09-04 2006-05-18 Akzo Nobel N.V. GLYCIN-SUBSTITUTED THIENO [2,3-d] PYRIMIDINES WITH COMBINED LH AND FSH-AGONISTIC EFFECT
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
EP1479684A4 (en) * 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
CN1326569C (en) 2002-02-26 2007-07-18 阿斯特拉曾尼卡有限公司 Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative
EP1579387A1 (en) 2002-12-20 2005-09-28 Koninklijke Philips Electronics N.V. Enhancing video images depending on prior image enhancements
ES2217956B1 (en) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF 4-AMINOTIENE (2,3-D) PIRIMIDIN-6-CARBONITRILE.
WO2006014647A2 (en) * 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
EP1806053A1 (en) 2004-10-25 2007-07-11 Nihon Nohyaku Co., Ltd. Herbicide compositions for upland farming and control method
KR20080041662A (en) * 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 Early Ovulation Prevention
TWI442932B (en) 2008-02-11 2014-07-01 Ferring Int Ct Sa Method for treating prostate cancer with GnRH antagonist
US20110172249A1 (en) 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
AU2012221800B2 (en) * 2011-02-23 2016-10-27 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
JP2012217679A (en) 2011-04-11 2012-11-12 Okumura Yu-Ki Co Ltd Pachinko game machine
SMT202200255T1 (en) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Crystalline form of 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin-6yl)phenyl)-3-methoxyurea
EP4223298A3 (en) 2013-03-15 2023-08-16 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
AU2015308987B2 (en) 2014-08-26 2021-02-18 Kaass Discovery As Methods, agents and compositions for treatment of inflammatory conditions
TWI744224B (en) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 Solid preparation
SI3518932T1 (en) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Treatment of prostate cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056739A1 (en) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
EP1266898A1 (en) * 2000-02-29 2002-12-18 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
EP1591446A1 (en) * 2003-01-29 2005-11-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAZUHIRO MIWA ET AL: "Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3- d ]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 14, 28 July 2011 (2011-07-28), pages 4998 - 5012, XP055012890, ISSN: 0022-2623, DOI: 10.1021/jm200216q *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180224B2 (en) 2012-09-28 2024-12-31 Takeda Pharmaceutical Company Limited Thienopyrimidine derivatives and production methods thereof
US12325714B2 (en) 2012-09-28 2025-06-10 Takeda Pharmaceutical Company Limited Compositions of thienopyrimidine derivatives
US10464945B2 (en) 2012-09-28 2019-11-05 Takeda Pharmaceutical Company Limited Crystalline forms of thienopyrimidine derivative
US11795178B2 (en) 2012-09-28 2023-10-24 Takeda Pharmaceutical Company Limited Compositions of thienopyrimidine derivatives
US10150778B2 (en) 2012-09-28 2018-12-11 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
US11053257B2 (en) 2012-09-28 2021-07-06 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
US11731983B2 (en) 2012-09-28 2023-08-22 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
US11583526B2 (en) 2016-09-30 2023-02-21 Myovant Sciences Gmbh Treatment of prostate cancer
US10449191B2 (en) 2016-09-30 2019-10-22 Myovant Sciences Gmbh Treatment of prostate cancer
US12097198B2 (en) 2016-09-30 2024-09-24 Sumitomo Pharma Switzerland Gmbh Treatment of prostate cancer
US11957684B2 (en) 2016-09-30 2024-04-16 Sumitomo Pharma Switzerland Gmbh Treatment of heavy menstrual bleeding associated with uterine fibroids
US12144809B1 (en) 2016-09-30 2024-11-19 Sumitomo Pharma Switzerland Gmbh Treatment of prostate cancer
US11033551B2 (en) 2016-09-30 2021-06-15 Myovant Sciences Gmbh Methods of treating uterine fibroids
US10786501B2 (en) 2016-09-30 2020-09-29 Myovant Sciences Gmbh Treatment of prostate cancer
US12336990B2 (en) 2016-09-30 2025-06-24 Sumitomo Pharma Switzerland Gmbh Treatment of prostate cancer
US12338249B2 (en) 2019-10-10 2025-06-24 Sumitomo Pharma Switzerland Gmbh Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
US12655154B2 (en) 2019-10-10 2026-06-16 Sumitomo Pharma Co., Ltd. Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
US12551447B2 (en) 2020-05-29 2026-02-17 Sumitomo Pharma Co., Ltd. Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Also Published As

Publication number Publication date
SI2900675T1 (en) 2019-06-28
US20230212184A1 (en) 2023-07-06
PT3415517T (en) 2022-05-13
RS58703B1 (en) 2019-06-28
US20170210753A1 (en) 2017-07-27
CN113372358A (en) 2021-09-10
EP3415517A1 (en) 2018-12-19
CN109053766B (en) 2021-06-22
AR092707A1 (en) 2015-04-29
US10464945B2 (en) 2019-11-05
CN109053766A (en) 2018-12-21
HUE059077T2 (en) 2022-11-28
EP3415517B1 (en) 2022-04-20
CA2881132C (en) 2020-11-24
HUE044048T2 (en) 2019-09-30
TW201808962A (en) 2018-03-16
JP2015532262A (en) 2015-11-09
US20220204525A1 (en) 2022-06-30
US20150266891A1 (en) 2015-09-24
ES2913753T3 (en) 2022-06-06
EP4119564A1 (en) 2023-01-18
CN104703992A (en) 2015-06-10
US12325714B2 (en) 2025-06-10
US20250368660A1 (en) 2025-12-04
CY1121641T1 (en) 2020-07-31
UY35058A (en) 2014-04-30
US10150778B2 (en) 2018-12-11
US12180224B2 (en) 2024-12-31
US11053257B2 (en) 2021-07-06
US20180319816A1 (en) 2018-11-08
CY1125151T1 (en) 2024-12-13
SMT201900255T1 (en) 2019-07-11
US11795178B2 (en) 2023-10-24
TWI641611B (en) 2018-11-21
TW201906847A (en) 2019-02-16
LT3415517T (en) 2022-06-10
TW201418262A (en) 2014-05-16
TWI602819B (en) 2017-10-21
US20250051353A1 (en) 2025-02-13
CN104703992B (en) 2019-03-05
US20190055261A1 (en) 2019-02-21
PT2900675T (en) 2019-05-28
US11731983B2 (en) 2023-08-22
US20220135585A1 (en) 2022-05-05
WO2014051164A2 (en) 2014-04-03
DK2900675T3 (en) 2019-06-03
ES2724206T3 (en) 2019-09-09
JP6250564B2 (en) 2017-12-20
PL2900675T3 (en) 2019-08-30
PL3415517T3 (en) 2022-07-04
EP2900675A2 (en) 2015-08-05
CA2881132A1 (en) 2014-04-03
CN113372358B (en) 2024-05-14
SI3415517T1 (en) 2022-06-30
US10544160B2 (en) 2020-01-28
HRP20190729T1 (en) 2019-06-14
US9758528B2 (en) 2017-09-12
RS63199B1 (en) 2022-06-30
HRP20220622T1 (en) 2022-06-24
EP2900675B1 (en) 2019-03-06
US20200361953A1 (en) 2020-11-19
DK3415517T3 (en) 2022-05-30
TWI663171B (en) 2019-06-21
TR201906318T4 (en) 2019-05-21
SMT202200255T1 (en) 2022-07-21
LT2900675T (en) 2019-05-27

Similar Documents

Publication Publication Date Title
CY1121641T1 (en) METHOD OF PREPARING A THIENOPYRIMIDINE DERIVATIVE
IL249706A0 (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncitial virus infections
PL3808749T3 (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
IL242872A0 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
IL255775A (en) Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
EP2905313A4 (en) METAL PARTICLE DISPERSION, ARTICLE AND FRITTED FILM USING THE SAME, AND PROCESS FOR PRODUCING SINTERED FILM
SG11201404969YA (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
SG11201505520WA (en) 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
SG10202110927VA (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
IL255386A0 (en) Processes and intermediates for the preparation of {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile
SI4247813T1 (en) Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3- yl)pyridof(2,3-d)pyrimidine-2,4(1h,3h)-dione
CA144272S (en) Front bumper for automobiles
WO2014205354A3 (en) Free base crystals
IL234772A0 (en) 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl (furo, thieno or pyrrolo)[2,3-d]pyrimidin-4-one derivatives for the treatment of cancer
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
MX2019003351A (en) N 3 -cyclically substituted thienouraciles and use thereof.
Iaroshenko et al. A general strategy for the synthesis of difluoromethyl-containing pyrazoles, pyridines and pyrimidines
WO2014114964A3 (en) Improved process for the preparation of prasugrel and intermediate thereof
HK1212334A1 (en) Process for the preparation of 2-amino-5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidine from 4-chloro-2,5-dimethoxypyrimidine
ZA201501733B (en) An improved process for the preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidine from 4-amino-2,5-dimethoxypyrimidine
IL265013B (en) Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
UA79045U (en) 2-amino-4,7-dimethyl-8-phenylcarbamoyl-9-(2-chlorophenyl)-3-cyanopyrido[2',3' : 4,5]thieno[2,3-b]pyridine
WO2013175486A8 (en) Method for producing "bi-metal" (ferrous/non-ferrous) tube
PL391460A1 (en) Multistage PLM process optimization method using the methods of classification and summaries supported by using genetic algorithms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13779938

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014557263

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2881132

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14432188

Country of ref document: US

Ref document number: 2013779938

Country of ref document: EP